HomeALCLS • EPA
add
Cellectis SA
Previous close
€1.35
Day range
€1.29 - €1.34
Year range
€1.01 - €3.03
Market cap
94.07M EUR
Avg Volume
238.41K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 15.16M | 662.06% |
Operating expense | 25.84M | -14.79% |
Net income | 5.92M | 114.17% |
Net profit margin | 39.05 | 101.86% |
Earnings per share | -0.16 | 71.93% |
EBITDA | -7.45M | 71.79% |
Effective tax rate | 7.99% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 143.25M | 4.79% |
Total assets | 383.54M | 14.74% |
Total liabilities | 252.51M | 1.18% |
Total equity | 131.03M | — |
Shares outstanding | 72.09M | — |
Price to book | 0.74 | — |
Return on assets | -6.85% | — |
Return on capital | -12.17% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 5.92M | 114.17% |
Cash from operations | -47.00K | -100.12% |
Cash from investing | -16.66M | -22.04% |
Cash from financing | 2.92M | -92.97% |
Net change in cash | -15.84M | -122.84% |
Free cash flow | -10.65M | -131.67% |
About
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Founded
1999
Website
Employees
219
